AIM: Functional in vivo studies on the mitochondrial thioredoxin system are hampered by the embryonic or larval lethal phenotypes displayed by murine or Drosophila knock-out models. Thus, the access to alternative metazoan knock-out models for the mitochondrial thioredoxin system is of critical importance. RESULTS: We report here the characterization of the mitochondrial thioredoxin system of Caenorhabditis elegans that is composed of the genes trx-2 and trxr-2. We demonstrate that the proteins thioredoxin 2 (TRX-2) and thioredoxin reductase 2 (TRXR-2) localize to the mitochondria of several cells and tissues of the nematode and that trx-2 and trxr-2 are upregulated upon induction of the mitochondrial unfolded protein response. Surprisingly, C. elegans trx-2 (lof ) and trxr-2 (null) single and double mutants are viable and display similar growth rates as wild-type controls. Moreover, the lack of the mitochondrial thioredoxin system does not affect longevity, reactive oxygen species production or the apoptotic program. Interestingly, we found a protective role of TRXR-2 in a transgenic nematode model of Alzheimer's disease (AD) that expresses human β-amyloid peptide and causes an age-dependent progressive paralysis. Hence, trxr-2 downregulation enhanced the paralysis phenotype, while a strong decrease of β-amyloid peptide and amyloid deposits occurred when TRXR-2 was overexpressed. INNOVATION: C. elegans provides the first viable metazoan knock-out model for the mitochondrial thioredoxin system and identifies a novel role of this system in β-amyloid peptide toxicity and AD. CONCLUSION: The nematode strains characterized in this work make C. elegans an ideal model organism to study the pathophysiology of the mitochondrial thioredoxin system at the level of a complete organism.
AIM: Functional in vivo studies on the mitochondrial thioredoxin system are hampered by the embryonic or larval lethal phenotypes displayed by murine or Drosophila knock-out models. Thus, the access to alternative metazoan knock-out models for the mitochondrial thioredoxin system is of critical importance. RESULTS: We report here the characterization of the mitochondrial thioredoxin system of Caenorhabditis elegans that is composed of the genes trx-2 and trxr-2. We demonstrate that the proteins thioredoxin 2 (TRX-2) and thioredoxin reductase 2 (TRXR-2) localize to the mitochondria of several cells and tissues of the nematode and that trx-2 and trxr-2 are upregulated upon induction of the mitochondrial unfolded protein response. Surprisingly, C. eleganstrx-2 (lof ) and trxr-2 (null) single and double mutants are viable and display similar growth rates as wild-type controls. Moreover, the lack of the mitochondrial thioredoxin system does not affect longevity, reactive oxygen species production or the apoptotic program. Interestingly, we found a protective role of TRXR-2 in a transgenic nematode model of Alzheimer's disease (AD) that expresses human β-amyloid peptide and causes an age-dependent progressive paralysis. Hence, trxr-2 downregulation enhanced the paralysis phenotype, while a strong decrease of β-amyloid peptide and amyloid deposits occurred when TRXR-2 was overexpressed. INNOVATION: C. elegans provides the first viable metazoan knock-out model for the mitochondrial thioredoxin system and identifies a novel role of this system in β-amyloid peptide toxicity and AD. CONCLUSION: The nematode strains characterized in this work make C. elegans an ideal model organism to study the pathophysiology of the mitochondrial thioredoxin system at the level of a complete organism.
Authors: Jörgen Stenvall; Juan Carlos Fierro-González; Peter Swoboda; Karunakar Saamarthy; Qing Cheng; Briseida Cacho-Valadez; Elias S J Arnér; Olof P Persson; Antonio Miranda-Vizuete; Simon Tuck Journal: Proc Natl Acad Sci U S A Date: 2011-01-03 Impact factor: 11.205
Authors: Cristina Nieto; Johann Almendinger; Stephan Gysi; Eva Gómez-Orte; Andres Kaech; Michael O Hengartner; Ralf Schnabel; Sergio Moreno; Juan Cabello Journal: J Cell Sci Date: 2010-06-15 Impact factor: 5.285
Authors: Ivan Nalvarte; Anastasios E Damdimopoulos; Christina Nystöm; Tomas Nordman; Antonio Miranda-Vizuete; Jerker M Olsson; Lennart Eriksson; Mikael Björnstedt; Elias S J Arnér; Giannis Spyrou Journal: J Biol Chem Date: 2004-10-07 Impact factor: 5.157
Authors: Alicia J Kowaltowski; Nadja C de Souza-Pinto; Roger F Castilho; Anibal E Vercesi Journal: Free Radic Biol Med Date: 2009-05-08 Impact factor: 7.376
Authors: Virginia Fonte; Vishantie Dostal; Christine M Roberts; Patrick Gonzales; Pascale N Lacor; Pascale Lacor; Pauline T Velasco; Jordi Magrane; Natalie Dingwell; Emily Y Fan; Michael A Silverman; Gretchen H Stein; Christopher D Link Journal: Mol Neurodegener Date: 2011-08-23 Impact factor: 14.195
Authors: Ehud Cohen; Deguo Du; Derek Joyce; Erik A Kapernick; Yuli Volovik; Jeffery W Kelly; Andrew Dillin Journal: Aging Cell Date: 2009-12-11 Impact factor: 9.304
Authors: Katie C McCallum; Bin Liu; Juan Carlos Fierro-González; Peter Swoboda; Swathi Arur; Antonio Miranda-Vizuete; Danielle A Garsin Journal: Genetics Date: 2016-02-26 Impact factor: 4.562
Authors: David Guerrero-Gómez; José Antonio Mora-Lorca; Beatriz Sáenz-Narciso; Francisco José Naranjo-Galindo; Fernando Muñoz-Lobato; Cristina Parrado-Fernández; Julen Goikolea; Ángel Cedazo-Minguez; Christopher D Link; Christian Neri; María Dolores Sequedo; Rafael P Vázquez-Manrique; Elena Fernández-Suárez; Veit Goder; Roser Pané; Elisa Cabiscol; Peter Askjaer; Juan Cabello; Antonio Miranda-Vizuete Journal: Cell Death Differ Date: 2019-02-15 Impact factor: 15.828
Authors: Fernando Muñoz-Lobato; María Jesús Rodríguez-Palero; Francisco José Naranjo-Galindo; Freya Shephard; Christopher J Gaffney; Nathaniel J Szewczyk; Shusei Hamamichi; Kim A Caldwell; Guy A Caldwell; Chris D Link; Antonio Miranda-Vizuete Journal: Antioxid Redox Signal Date: 2013-07-03 Impact factor: 8.401
Authors: Francisco Gil-Bea; Susanne Akterin; Torbjörn Persson; Laura Mateos; Anna Sandebring; Javier Avila-Cariño; Angel Gutierrez-Rodriguez; Erik Sundström; Arne Holmgren; Bengt Winblad; Angel Cedazo-Minguez Journal: EMBO Mol Med Date: 2012-08-30 Impact factor: 12.137